DarioHealth Corp.Find Ratings Reports
DARIOHEALTH CORP's gross profit margin for the first quarter of its fiscal year 2021 has decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. DARIOHEALTH CORP is extremely liquid. Currently, the Quick Ratio is 6.97 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 627.77% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY21||Q1 FY20|
|Net Sales ($mil)||3.6||1.67|
|Net Income ($mil)||-14.97||-9.89|
|Balance Sheet||Q1 FY21||Q1 FY20|
|Cash & Equiv. ($mil)||81.42||16.01|
|Total Assets ($mil)||124.19||20.03|
|Total Debt ($mil)||0.5||0.67|
|Profitability||Q1 FY21||Q1 FY20|
|Gross Profit Margin||46.48||49.49|
|Return on Assets||-27.79||-111.07|
|Return on Equity||-32.82||-172.97|
|Debt||Q1 FY21||Q1 FY20|
|Share Data||Q1 FY21||Q1 FY20|
|Shares outstanding (mil)||15.4||3.1|
|Div / share||0.0||0.0|
|Book value / share||7.29||4.97|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||267722.0||289763.0|
HOLD. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 2.01 indicates a significant discount versus the S&P 500 average of 4.59 and a significant discount versus the subsector average of 11.35. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. The valuation analysis reveals that, DARIOHEALTH CORP seems to be trading at a premium to investment alternatives.
|DRIO NM||Peers 96.70||DRIO NM||Peers 182.46|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
DRIO's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
DRIO's P/CF is negative making the measure meaningless.
|DRIO NM||Peers 171.94||DRIO NA||Peers 0.86|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
DRIO's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|DRIO 2.01||Peers 11.35||DRIO 47.39||Peers 87.24|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
DRIO is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, DRIO is expected to significantly trail its peers on the basis of its earnings growth rate.
|DRIO 23.70||Peers 10.49||DRIO 36.08||Peers 22.72|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
DRIO is trading at a significant premium to its subsector.
Higher. A sales growth rate that exceeds the subsector implies that a company is gaining market share.
DRIO has a sales growth rate that significantly exceeds its peers.